跳至主要内容
临床试验/NCT02641665
NCT02641665Unknown不适用

Measurement of Four Plasma Biomarkers for Risk Stratification and Determination of Functional Recovery After Cardiac Valve Surgery

University of Liege1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2016年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
250
试验地点
1
主要终点
Composite primary outcome

研究概览

简要总结

The level of four biomarkers will be measured in the patients' plasma after induction of anaesthesia. There biomarkers are NT-ProBNP, ST2, Galectin-3 and GDF-15. The level of these marker will then be correlated with early (30 days) and late (one year) patients' prognosis and with functional recovery (MLHFQ score).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Elective/urgent aortic or mitral valve surgery in isolation or combined with CABG

排除标准

  • Emergency or salvage surgery
  • Inability to consent
  • Previous cardiac surgery
  • Stage IV or V CDK (GFR ≤ 30 ml/min) or dialysis
  • Active Endocarditis
  • Liver cirrhosis
  • Chronic atrial fibrillation
  • Pacemaker

结局指标

主要结局

Composite primary outcome

时间窗: 30 days

In hospital or 30-days mortality or inotropic support during more than 48 hours or lengthy of ICU stay longer than 5 days

次要结局

  • one year mortality(1 year)
  • ICU readmission(30 days)
  • NYHA(1 year)
  • Post-operative AKI(48 hours)
  • Ejection fraction(1 year)
  • reshopitalisation(1 year)
  • MLHFQ(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jean François Brichant

Professor, Head of Department

University of Liege

研究点 (1)

Loading locations...

相似试验